Is KROS' KER-065 the Next Breakthrough in DMD Space?

Key Takeaways Keros Therapeutics is developing KER-065, an inhibitor for treating Duchenne muscular dystrophy.KROS reported phase I top-line data in March 2025 and received FDA orphan drug designation in August 2025.Keros plans to start a phase II DMD trial in Q1 2026 after halting cibotercept to focus on KER-065.Keros Therapeutics (KROS) is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transfor ...